Transcode Therapeutics Inc
NASDAQ:RNAZ
Intrinsic Value
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. [ Read More ]
The intrinsic value of one
RNAZ
stock under the Base Case scenario is
0.477
USD.
Compared to the current market price of 0.485 USD,
Transcode Therapeutics Inc
is
Overvalued by 2%.
Transcode Therapeutics Inc's market capitalization is 2.8m USD.
RNAZ stock price is 0.485 USD.
RNAZ stock (0.477 USD) is 2% less than its price (0.485 USD).
RNAZ. Open Relative Valuation
RNAZ.
RNAZ has negative Free Cash Flow for the last twelve months.
RNAZ's short-term assets (4m USD) exceed its short-term liabilties (3m USD).
RNAZ's long-term assets (5m USD) exceed its long-term liabilties (4m USD).
RNAZ has negative Operating Income for the last twelve months.
RNAZ has negative Net Income for the last twelve months.
RNAZ's ROE (Return on Equity) for the past 12 months is negative and is equal to -760%.
RNAZ's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 10 663%.
RNAZ has negative three-year average ROE (Return on Equity): -247%. The company is not efficient at transforming stockholders' equity into net income.
RNAZ has very high three-year average ROIC (Return on Invested Capital): 3 166%. The company is very efficient at using invested capital to generate operating income.
RNAZ's D/E (Debt to Equity) is very low and is equal to 0.
RNAZ's Altman Z-Score is very low and is equal to -18.87.
RNAZ doesn't generate enough operating income (-19m USD) to safely cover interest payments on its debt (33k USD).
Valuation Backtest
Transcode Therapeutics Inc
Run backtest to discover the historical profit from buying and selling
RNAZ
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Transcode Therapeutics Inc
Balance Sheet Decomposition
Transcode Therapeutics Inc
| Current Assets | 4.5m |
| Cash & Short-Term Investments | 2.8m |
| Other Current Assets | 1.7m |
| Non-Current Assets | 714.3k |
| PP&E | 602.4k |
| Other Non-Current Assets | 111.9k |
| Current Liabilities | 3.5m |
| Accounts Payable | 2m |
| Accrued Liabilities | 1.5m |
| Other Current Liabilities | 27.1k |
| Non-Current Liabilities | 38.3k |
| Other Non-Current Liabilities | 38.3k |
Earnings Waterfall
Transcode Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-19.4m
USD
|
|
Operating Income
|
-19.4m
USD
|
|
Other Expenses
|
872.4k
USD
|
|
Net Income
|
-18.5m
USD
|
Free Cash Flow Analysis
Transcode Therapeutics Inc
What is Free Cash Flow?
RNAZ Profitability Score
Profitability Due Diligence
Transcode Therapeutics Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Transcode Therapeutics Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
RNAZ Solvency Score
Solvency Due Diligence
Transcode Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Transcode Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RNAZ Price Targets Summary
Transcode Therapeutics Inc
Ownership
RNAZ Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
RNAZ Price
Transcode Therapeutics Inc
| Average Annual Return | -53.99% |
| Standard Deviation of Annual Returns | 31.45% |
| Max Drawdown | -100% |
| Market Capitalization | 2.8m USD |
| Shares Outstanding | 5 808 050 |
| Percentage of Shares Shorted | 0.69% |
Company Profile
Transcode Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2021-04-28. The company has developed a modular, iron oxide nanoparticle-based nanocarrier system for the delivery of RNA therapeutics to tumors. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include two solid tumor programs such as TTX-siPDL1, a small interfering RNA (siRNA)based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLin28b, a siRNA-based inhibitor of RNA-binding protein LIN28B.
Contact
IPO
Employees
Officers
The intrinsic value of one
RNAZ
stock under the Base Case scenario is
0.477
USD.
Compared to the current market price of 0.485 USD,
Transcode Therapeutics Inc
is
Overvalued by 2%.
You don't have any saved screeners yet
